Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Tonix Pharmaceuticals Hol... (TNXP)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.23

-0.03 (-10.30%)

At close: Jan 14, 2025, 3:59 PM

0.23

1.98%

Pre-market Jan 15, 2025, 06:30 AM EST

undefined% (undefined)

Bid	0.23
Market Cap	42.44M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-80.39
PE Ratio (ttm)	0
Forward PE	n/a
Analyst	Strong Buy

Ask	0.23
Volume	45,654,981
Avg. Volume (20D)	106,750,662
Open	0.26
Previous Close	0.26
Day's Range	0.23 - 0.26
52-Week Range	0.12 - 12.48
Beta	undefined

About TNXP

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, auto...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 10, 2012

Employees 103

Stock Exchange NASDAQ

Ticker Symbol TNXP

Website https://www.tonixpharma.com

Analyst Forecast

According to 2 analyst ratings, the average rating for TNXP stock is "Strong Buy." The 12-month stock price forecast is $53.5, which is an increase of 23457.90% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Tonix Pharmaceuticals Holding Corp. is scheduled to release its earnings on Mar 31, 2025, during market hours.
Analysts project revenue of $3.40M, reflecting a -10.03% YoY shrinking and earnings per share of -2.97, making a -89.21% decrease YoY.

Why Price Moved

3 months ago · Source

+12.83%

Tonix Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription

3 months ago · Source

+12.77%

Tonix Pharmaceuticals shares are trading higher after the company announced it submitted an NDA for TNX-102 SL to the FDA for fibromyalgia treatment. The non-opioid analgesic showed significant pain reduction in Phase 3 studies and received fast-track designation.

News

6 months ago · investorplace.com

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?

Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling on Thursday after the biopharmaceutical company announced a proposed public offering for its shares. Tonix Pharmaceuticals doesn't have the finer...

7 months ago · investorplace.com

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024

As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuat...

7 months ago · investorplace.com

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 40% Today?

Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling on Wednesday after the biopharmaceutical company announced a proposed public offering for its shares. Tonix Pharmaceuticals doesn't provide any f...

7 months ago · investorplace.com

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 31% Today?

Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling hard on Monday after the company's shares underwent a reverse stock split this morning. That reverse stock split saw Tonix Pharmaceuticals consol...

9 months ago · investorplace.com

3 Biotech Stocks to Dump Before They Go to Zero

It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason.

9 months ago · investorplace.com

3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million

Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves.

10 months ago · investorplace.com

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond

In almost every situation, investors should stay away from penny stocks. They're extremely speculative and they tend to facilitate delusions of grandeur.

1 year ago · marketwatch.com

Tonix shares sink 29% on discontinued development on depression treatment

Shares of Tonix Pharmaceuticals TNXP fell Tuesday after the company said it would discontinue development of its treatment for major depressive disorder.

1 year ago · proactiveinvestors.com

Tonix Pharmaceuticals expects topline results from migraine prevention study in December

Tonix Pharmaceuticals (NASDAQ:TNXP) said it expects to receive the topline results from its 88-patient Phase 2 PREVENTION study of its investigation drug TNX-1900 for the prevention of migraine headac...

1 year ago · investorplace.com

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 29% Today?

Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling hard on Friday after the clinical-stage biopharmaceutical company priced a share offering. According to a press release from Tonix Pharmaceutical...